Name in SEC filings: Zai Lab Ltd
| Program | Event | Stage | Stated timing | Filing |
|---|---|---|---|---|
| ZL-1503 SAD | /data readout | Phase 1 | in the second half of 2026 | 8-K · |
| ZL-1503 MAD | Topline/data readout | Stage not stated | in the first half of 2027 | 8-K · |
| ZL-6201 | Topline/data readout | Phase 1 | in the first half of 2027 | 8-K · |
| Zocilurtatug pelitecan (DLLEVATE) | Enrollment completion | Phase 3 | in the first half of 2027 | 8-K · |
| Elegrobart | Topline/data readout | Phase 3 | in 2027 | 8-K · |
| ZL-1222 | Other | Phase 1 | in 2027 | 8-K · |
| ZL-1311 | submission | Phase 1 | by year-end 2026 | 8-K · |
Source: ORION, orionbiotechai.com/company/ZLAB, data as of Oct 17, 2026
https://www.orionbiotechai.com/company/ZLAB
ZL-1503 SAD · Topline/data readout · in the second half of 2026
SEC sources last checked .
○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.
Topline/data readoutin the second half of 2026
Stage: Phase 1SEC filing · “Phase 1/1b”
Public float: $3,800,000,000 · as of · SEC filing
ZL-1503 (IL-13/IL-31Rα): Completed enrollment in the single ascending dose (SAD) portion of the Phase 1/1b study of ZL-1503 in healthy volunteers, with initial PK, PD, safety and immunogenicity data expected in the second half of 2026.
8-K · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-12)
Topline/data readoutin the first half of 2027
Stage: Not stated
Public float: $3,800,000,000 · as of · SEC filing
Initial clinical data from the MAD portion expected in the first half of 2027.
SEC timing context:
ZL-1503 (IL-13/IL-31Rα) •Report initial first-in-human data from the SAD portion of the global Phase 1/1b study in healthy volunteers, including pharmacokinetics (PK), half-life, pharmacodynamic biomarkers (including pSTAT6), and safety, in the second half of 2026. •Continue enrollment in the MAD portion of the Phase 1/1b study in patients with atopic dermatitis.
8-K · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2027-06)
Topline/data readoutin the first half of 2027
Stage: Phase 1SEC filing · “Phase 1a”
Public float: $3,800,000,000 · as of · SEC filing
Provide topline results from the dose escalation portion of the global Phase 1a/b study evaluating ZL-6201 in patients with sarcoma and selected tumors in the first half of 2027.
8-K · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2027-06)
Enrollment completionin the first half of 2027
Stage: Phase 3SEC filing · “Phase 3”
Public float: $3,800,000,000 · as of · SEC filing
Second-Line Plus ES-SCLC: Complete enrollment in the global pivotal Phase 3 DLLEVATE study in the first half of 2027 followed by a planned interim analysis with the potential to support a BLA submission for accelerated approval.
SEC timing context:
Zocilurtatug Pelitecan (zoci, DLL3-Targeting ADC; formerly ZL-1310)
8-K · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2027-06)
Topline/data readoutin 2027
Stage: Phase 3SEC filing · “Phase 3”
Public float: $3,800,000,000 · as of · SEC filing
Zai Lab to provide topline results from the China Phase 3 registrational study in 2027.
SEC timing context:
Elegrobart (Anti-IGF-1R, subcutaneous) •Zai Lab to complete enrollment in the Phase 3 registrational study for the treatment of thyroid eye disease in China in the third quarter of 2026.
8-K · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2027-12)
Otherin 2027
Stage: Phase 1SEC filing · “Phase 1”
Public float: $3,800,000,000 · as of · SEC filing
Submit an IND application in the U.S. and initiate a global Phase 1 study in 2027.
SEC timing context:
ZL-1222 (PD-1/IL-12)
8-K · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2027-12)
NDA/BLA submissionby year-end 2026
Stage: Phase 1SEC filing · “Phase 1”
Public float: $3,800,000,000 · as of · SEC filing
Submit an IND application in the U.S. by year-end 2026 and initiate a global Phase 1 study in the first half of 2027.
SEC timing context:
ZL-1311 (MUC17/CD3)
8-K · Filed · Last checked
Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .
| Program / event | Stated period and SEC wording | Disclosure in stated period |
|---|---|---|
| ElegrobartClinical results | in 2027“Zai Lab to provide topline results from the China Phase 3 registrational study in 2027.” Filed · EX-99.1 | Period not started The stated period has not started yet, so there is nothing to compare. |
| ZL-1222Other | in 2027“Submit an IND application in the U.S. and initiate a global Phase 1 study in 2027.” Filed · EX-99.1 | Period not started The stated period has not started yet, so there is nothing to compare. |
| ZL-1311Submission | by year-end 2026“Submit an IND application in the U.S. by year-end 2026 and initiate a global Phase 1 study in the first half of 2027.” Filed · EX-99.1 | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| ZL-1503 MADClinical results | in the first half of 2027“Initial clinical data from the MAD portion expected in the first half of 2027.” Filed · EX-99.1 | Period not started The stated period has not started yet, so there is nothing to compare. |
| ZL-1503 SADClinical results | in the second half of 2026“ZL-1503 (IL-13/IL-31Rα): Completed enrollment in the single ascending dose (SAD) portion of the Phase 1/1b study of ZL-1503 in healthy volunteers, with initial PK, PD, safety and immunogenicity data expected in the second half of 2026.” Filed · EX-99.1 | Still within period As of Oct 19, 2026 |
| ZL-6201Clinical results | in the first half of 2027“Provide topline results from the dose escalation portion of the global Phase 1a/b study evaluating ZL-6201 in patients with sarcoma and selected tumors in the first half of 2027.” Filed · EX-99.1 | Period not started The stated period has not started yet, so there is nothing to compare. |
| Zocilurtatug pelitecan (DLLEVATE)Enrollment completion | in the first half of 2027“Second-Line Plus ES-SCLC: Complete enrollment in the global pivotal Phase 3 DLLEVATE study in the first half of 2027 followed by a planned interim analysis with the potential to support a BLA submission for accelerated approval.” Filed · EX-99.1 | Period not started The stated period has not started yet, so there is nothing to compare. |
“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.
Suggest an SEC timing statement to add for ZLAB. You can include the original filing link in your note. The founder reads each request by hand.
Or email ORION.
See ZLAB in the calendar · Review labels and methodology